Drug Trial Radar · NCT07450482
Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD
Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Jul 22, 2025
Primary completion
Sep 25, 2025
Study completion Sep 25, 2025
Sponsor
- Lead sponsor
- Joincare Pharmaceutical Group Industry Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Livzon Pharmaceutical Group Inc.
- First posted
- Mar 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase IIa study is to evaluate the safety, efficacy, and pharmacokinetics of JKN2304 Inhalation Solution in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). The study is a multicenter, randomized, double-blind, placebo-controlled, and active-controlled (open-label) trial. Participants are randomized to receive JKN2304 (2 mg once daily or 2 mg twice daily), Placebo, or Formoterol Fumarate Inhalation Solution for a treatment period of 14 days.
Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- COPD
Interventions
JKN2304 Inhalation SolutionDrug
Specification: 3ml:2mg. Administered via nebulizer.
PlaceboOther
Specification: 3ml:0mg. Matches the appearance of the investigation product. Administered via nebulizer.
Formoterol Fumarate Inhalation SolutionDrug
Specification: 2ml:20μg. Administered via nebulizer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From signing of informed consent through the safety follow-up visit (Day 21)
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Zhangzhou Hospital, Fujian Province
Zhangzhou, Fujian, China
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
Liuyang People's Hospital
Guankou, Hunan, China
Jiangyin Hospital of Traditional Chinese Medicine
Jiangyin, Jiangsu, China
The Affiliated Hospital of Yangzhou University
Yangzhou, Jiangsu, China
Weifang Second People's Hospital
Weifang, Shandong, China
Huadong Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Shanghai Pudong New Area People's Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.